津药药业
(600488)
| 流通市值：45.53亿 | | | 总市值：45.53亿 |
| 流通股本：10.92亿 | | | 总股本：10.92亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 785,765,994.13 | 3,215,285,232.59 | 2,572,214,567.52 | 1,800,984,341.21 |
| 营业收入 | 785,765,994.13 | 3,215,285,232.59 | 2,572,214,567.52 | 1,800,984,341.21 |
| 二、营业总成本 | 693,723,469.32 | 2,936,885,787.12 | 2,279,961,906.11 | 1,568,445,221.99 |
| 营业成本 | 465,071,873.83 | 1,754,090,289.96 | 1,429,442,530.13 | 968,875,212.21 |
| 税金及附加 | 9,164,114.59 | 39,788,190.75 | 30,180,105.89 | 20,183,416.75 |
| 销售费用 | 88,859,231.04 | 569,973,577.12 | 435,246,501.67 | 339,485,156.31 |
| 管理费用 | 90,833,119.51 | 360,608,288.94 | 240,384,816.41 | 152,859,030.38 |
| 研发费用 | 37,752,655.26 | 204,492,012.31 | 135,810,466.23 | 83,839,615.08 |
| 财务费用 | 2,042,475.09 | 7,933,428.04 | 8,897,485.78 | 3,202,791.26 |
| 其中:利息费用 | 5,146,270.47 | 28,816,379.9 | 22,846,315.95 | 15,795,524.67 |
| 其中:利息收入 | 2,571,093.3 | 8,123,858.11 | 6,259,651.83 | 4,109,155.59 |
| 加:公允价值变动收益 | - | - | - | 0 |
| 加:投资收益 | -608,206.44 | -9,091,758.55 | -427,665.44 | 1,040,640.69 |
| 资产处置收益 | -9,235.51 | -33,485.38 | -411,888.27 | -194,484.96 |
| 资产减值损失(新) | -17,987,733.97 | -72,186,782.86 | -56,623,669.01 | -53,747,952.66 |
| 信用减值损失(新) | -470,479.88 | -273,649.8 | -186,397.01 | -93,292.18 |
| 其他收益 | 6,451,221.42 | 28,740,388.69 | 18,825,069.66 | 13,127,120.17 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 79,418,090.43 | 225,554,157.57 | 253,428,111.34 | 192,671,150.28 |
| 加:营业外收入 | 218,442.88 | 1,852,145.79 | 2,195,464.13 | 1,875,783.69 |
| 减:营业外支出 | 18,782.61 | 893,212.81 | 244,099.71 | 216,273.63 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 79,617,750.7 | 226,513,090.55 | 255,379,475.76 | 194,330,660.34 |
| 减:所得税费用 | 4,157,578 | 18,300,542.36 | 16,510,299.25 | 16,927,650.13 |
| 六、净利润 | 75,460,172.7 | 208,212,548.19 | 238,869,176.51 | 177,403,010.21 |
| 持续经营净利润 | 75,460,172.7 | 208,212,548.19 | 238,869,176.51 | 177,403,010.21 |
| 归属于母公司股东的净利润 | 58,050,125.92 | 133,450,642.68 | 186,695,386.54 | 142,020,246.39 |
| 少数股东损益 | 17,410,046.78 | 74,761,905.51 | 52,173,789.97 | 35,382,763.82 |
| (一)基本每股收益 | 0.05 | 0.12 | 0.17 | 0.13 |
| (二)稀释每股收益 | 0.05 | 0.12 | 0.17 | 0.13 |
| 八、其他综合收益 | 446,865.49 | 61,586,860.24 | 2,750,774.5 | 2,704,989.9 |
| 归属于母公司股东的其他综合收益 | 446,865.49 | 61,586,860.24 | 2,750,774.5 | 2,704,989.9 |
| 九、综合收益总额 | 75,907,038.19 | 269,799,408.43 | 241,619,951.01 | 180,108,000.11 |
| 归属于母公司股东的综合收益总额 | 58,496,991.41 | 195,037,502.92 | 189,446,161.04 | 144,725,236.29 |
| 归属于少数股东的综合收益总额 | 17,410,046.78 | 74,761,905.51 | 52,173,789.97 | 35,382,763.82 |
| 公告日期 | 2025-04-29 | 2025-03-27 | 2024-10-30 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |